$0.00
(Market cap
$4 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-49 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
1.2
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
140,028,000
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pear Therapeutics Inc (PEAR)
| -99.3 | 75.0 | -98.0 | -99.6 | -- | -- | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Pear Therapeutics Inc (PEAR)
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and... stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology. Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Founder, Pres, CEO & Director
Dr. Corey M. McCann M.D., Ph.D.
-
Founder, Pres, CEO & Director
Dr. Corey M. McCann M.D., Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pear Therapeutics Inc (PEAR)
What is the current share price of Pear Therapeutics Inc (PEAR) Today?
The share price of Pear Therapeutics Inc (PEAR) is $0.01 (NASDAQ) as of 20-Jun-2023 09:30 EDT. Pear Therapeutics Inc (PEAR) has given a return of -99.63% in the last 1 years.
What is the current PB & PE ratio of Pear Therapeutics Inc (PEAR)?
Since, TTM earnings of Pear Therapeutics Inc (PEAR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
--
|
--
|
What is the 52 Week High and Low of Pear Therapeutics Inc (PEAR)?
The 52-week high and low of Pear Therapeutics Inc (PEAR) are Rs -- and Rs -- as of 21-Jun-2026.
What is the market cap of Pear Therapeutics Inc (PEAR)?
Pear Therapeutics Inc (PEAR) has a market capitalisation of $ 4 Mln as on 20-Jun-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Pear Therapeutics Inc (PEAR)?
Before investing in Pear Therapeutics Inc (PEAR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.